Sigma Labs Announces Closing of $9.7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Rhea-AI Summary

Sigma Labs (NASDAQ:SGLB) has successfully completed a $9.7 million registered direct offering, selling 2,190,000 shares of common stock at a price of $4.445 each, alongside short-term warrants. The warrants, priced at $4.32, become exercisable upon shareholder approval to increase authorized shares from 12 million to 24 million. The proceeds will be used for operations, product development, and working capital. The offering was managed by H.C. Wainwright & Co.

Positive

• Gross proceeds of approximately $9.7 million will enhance company operations and product development.
• The offering allows Sigma Labs to increase its authorized shares, facilitating potential growth.

Negative

• Shareholder dilution risk due to the increase in authorized shares from 12 million to 24 million.

SANTA FE, NM / ACCESSWIRE / March 26, 2021 / Sigma Labs, Inc. (NASDAQ:SGLB) ("Sigma Labs" or the "Company"), a leading developer of quality assurance software for the commercial metal 3D printing industry, today announced the closing of its previously announced registered direct offering of 2,190,000 of its shares of common stock priced at-the-market under Nasdaq rules. Additionally, Sigma Labs also issued to the investors short-term warrants to purchase up to an aggregate of 2,190,000 shares of common stock in a concurrent private placement. The combined purchase price for one common stock and a warrant to purchase one share of common stock was $4.445. The warrants have an exercise price of $4.32 per share, are exercisable upon the Company's receipt of shareholder approval to increase its number of authorized shares of common stock from 12 million shares to 24 million shares for a period of two years.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds from the registered direct offering and concurrent private placement were approximately $9.7 million before deducting placement agent fees and other estimated offering expenses. Sigma Labs intends to use the net proceeds from this offering for the Company's operations, including the development and marketing of its products and services, and working capital and general corporate purposes.

The common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered pursuant to a "shelf" registration statement (File No. 333-225377) that was filed with the U.S. Securities and Exchange Commission ("SEC") on June 1, 2018 and declared effective on June 14, 2018. Such shares of common stock were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock was filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of common stock may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (212) 856-5711.

The warrants issued in the concurrent private placement and shares of common stock underlying the warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Sigma Labs

Sigma Labs Inc. is a leading provider of in-process quality assurance (IPQA®) software to the additive manufacturing industry. Sigma Labs specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process, enabling significant cost-savings and production efficiencies. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the intended use of net proceeds from the registered direct offering, whether the Company can successfully develop the Company's proprietary technologies and whether the market will accept the Company's products and services, and the impact of COVID-19, general economic, industry or political conditions in the United States or internationally as well as other risk factors and business considerations described in the Company's Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Contact:

Investor Contact:
Chris Tyson
Managing Director
MZ Group - MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us

Company Contact:
Steven Gersten
Sigma Internal IR
813-334-9745
investors@sigmalabsinc.com

SOURCE: Sigma Labs, Inc.

View source version on accesswire.com:
https://www.accesswire.com/637702/Sigma-Labs-Announces-Closing-of-97-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules

FAQ

What was the total amount raised by Sigma Labs in the recent offering?

Sigma Labs raised approximately $9.7 million from the registered direct offering.

What is the exercise price of the warrants issued by Sigma Labs?

The exercise price of the warrants is $4.32 per share.

When will the warrants become exercisable?

The warrants will be exercisable upon shareholder approval to increase the number of authorized shares.

What will Sigma Labs use the proceeds from the offering for?

The proceeds will be used for operations, product development, and working capital.

Who managed the offering for Sigma Labs?

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.